Tue, Jul 22, 2014, 5:03 PM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • peterdom1 peterdom1 Oct 18, 2011 4:59 PM Flag

    Let's go to the Tape

    Cubist takes us out @ 19-19.50 before earnings, why settle for 47M in revenue when they can take us our for cash and stock, they have about 350M according to filings and our 100M+ and the Astrellas royalty gives them room to offer up to a 40-50% premiom now. Stay tuned just a thought/

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Peter, can you bring me up to speed on your post?

      They were hired by OPTR to assist the launch of DIFICID. Was part of their incentive OPTR common?

      Cubist earnings due out today at 4PM.

      <<Marketing expenses for the second quarter of 2011 increased $6.3 million compared to the second quarter of 2010 due to Optimer's efforts to establish a commercial infrastructure and prepare for the launch of DIFICID, including the hiring of approximately 100 marketing and sales staff. General and administrative expenses increased $3.8 million compared to the second quarter of 2010, primarily because of higher compensation expense due to additional headcount as well as higher recruitment, consulting, facilities and legal expenses. Research and development expenses increased $4.2 million compared to the second quarter of 2010 due to higher health economics research, pharmacovigilance, medical affairs and publication expenses, as well as higher research and development expenses by OBI associated with the OPT-822 Phase 2/3 trial in breast cancer.>> (from their 2Q earnings report)

 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.